Can Aclaris Therapeutics Inc (NASDAQ:ACRS)’s Tomorrow be Different? The Stock Had Increase in Shorts

June 16, 2018 - By reb123z

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Logo

The stock of Aclaris Therapeutics Inc (NASDAQ:ACRS) registered an increase of 4.83% in short interest. ACRS’s total short interest was 5.54 million shares in June as published by FINRA. Its up 4.83% from 5.28 million shares, reported previously. With 202,300 shares average volume, it will take short sellers 27 days to cover their ACRS’s short positions. The short interest to Aclaris Therapeutics Inc’s float is 21.88%.

The stock increased 0.76% or $0.15 during the last trading session, reaching $19.93. About 504,383 shares traded or 106.74% up from the average. Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has declined 24.32% since June 16, 2017 and is downtrending. It has underperformed by 36.89% the S&P500.

Aclaris Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing topical drugs to address various unmet needs in dermatology. The company has market cap of $615.96 million. The Company’s lead drug candidate is A-101, a hydrogen peroxide topical solution, which is in Phase III clinical trials for the treatment of seborrheic keratosis , a common non-malignant skin tumor. It currently has negative earnings. The firm is also developing A-101 as a prescription treatment for common warts.

More notable recent Aclaris Therapeutics, Inc. (NASDAQ:ACRS) news were published by: Seekingalpha.com which released: “Aclaris Therapeutics expands leadership team” on June 15, 2018, also Nasdaq.com with their article: “Aclaris Therapeutics Announces Issuance of Additional Orange Book Listable Patent Covering ESKATA” published on May 30, 2018, Nasdaq.com published: “Landec Corporation to Nominate Two New Board Directors” on May 24, 2018. More interesting news about Aclaris Therapeutics, Inc. (NASDAQ:ACRS) were released by: Streetinsider.com and their article: “Aclaris Therapeutics (ACRS) Announces Publication of Phase 3 Data Leading to FDA Approval of ESKATA” published on June 12, 2018 as well as Nasdaq.com‘s news article titled: “Phase 3 data in the online Journal of the American Academy of Dermatology show Aclaris’ ESKATAâ„¢ is safe and …” with publication date: June 12, 2018.

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: